Bawei Chenxiang Pills Exert Anti‐Myocardial Ischemia Effect by Inhibiting Inflammation Through the TLR4/NF‐κB/NLRP3 Signaling Pathway
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202503537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Lulu Kang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P. R. China. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Signal Transduction, Myocardial Ischemia, Inflammation. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tibet Autonomous Region Science and Technology Programs Key R&D Programs.
Abstract (Originalsprache)
Ischemic heart disease (IHD) ranks among the most lethal cardiovascular diseases globally. As one of the traditional ethnic medical systems, Tibetan medicine has demonstrated remarkable therapeutic efficacy. In this study, the ethanol extract of Bawei Chenxiang Pills (CT) was evaluated in an acute myocardial ischemia mouse model. The results demonstrated that CT significantly enhanced myocardial contractility and inhibited ventricular dilation, improved cardiac histopathology, lowered the heart‐to‐body weight ratio in AMI mice, and reduced the release of lactate dehydrogenase and creatine kinase‐MB, downregulated inflammatory mediators interleukin (IL)‐1β, IL‐18, and tumor necrosis factor (TNF)‐α, and inhibited activation of the toll‐like receptor 4 (TLR4)/nuclear factor‐κB (NF‐κB)/NOD‐like receptor pyrin domain‐containing 3 (NLRP3) signaling pathway, thereby protecting myocardial cell membrane integrity. Moreover, in the lipopolysaccharide/adenosine 5'‐triphosphate‐induced inflammatory RAW264.7 cell model, CT reduced nitric oxide levels in the cell supernatant, inhibited NF‐κB nuclear translocation, reduced NLRP3 protein expression, and suppressed the transcription of IL‐1β, IL‐18, and TNF‐α. Overall, these findings suggest that CT exerts significant anti‐myocardial ischemia effects, primarily by modulating the TLR4/NF‐κB/NLRP3 pathway to attenuate myocardial inflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Research Institute of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, P. R. China.
- Tibet Ganlu Tibetan Medicine Co., Ltd., Lhasa, P. R. China.
ORCID-Profile: Xingyun Chai
Förderung
- National Natural Science Foundation of China
- Tibet Autonomous Region Science and Technology Programs Key R&D Programs
Zitieren
APA
Kang, L., Yang, G., Ding, Q., Wang, J., Tosheel, U. B., Xiao, Y., Zhou, F., Gao, X., Norbu, K., & Chai, X. (2026). Bawei Chenxiang Pills Exert Anti‐Myocardial Ischemia Effect by Inhibiting Inflammation Through the TLR4/NF‐κB/NLRP3 Signaling Pathway. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202503537
Vancouver
Kang L, Yang G, Ding Q, Wang J, Tosheel UB, Xiao Y, et al. Bawei Chenxiang Pills Exert Anti‐Myocardial Ischemia Effect by Inhibiting Inflammation Through the TLR4/NF‐κB/NLRP3 Signaling Pathway. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202503537
BibTeX
@article{Kang2026,
author = {Kang, Lulu and Yang, Guodong and Ding, Qiuyuan and Wang, Jiatong and Tosheel, Ulzhi Batu and Xiao, Yize and Zhou, Feng and Gao, Xiaoli and Norbu, Kelsang and Chai, Xingyun},
title = {Bawei Chenxiang Pills Exert Anti‐Myocardial Ischemia Effect by Inhibiting Inflammation Through the TLR4/NF‐κB/NLRP3 Signaling Pathway},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202503537}
}
EUVIMED